These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 7529609)

  • 1. Assessment of complete remission after 2-chlorodeoxyadenosine for hairy cell leukemia: utility of marrow immunostaining and measurement of splenic index.
    Tallman MS; Hakimian D; Dyrda S; Kiley C; Nemcek A; Peterson L
    Leuk Lymphoma; 1994; 14 Suppl 1():133-8. PubMed ID: 7529609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia.
    Hakimian D; Tallman MS; Kiley C; Peterson L
    Blood; 1993 Sep; 82(6):1798-802. PubMed ID: 7691237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
    Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
    Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia.
    Ellison DJ; Sharpe RW; Robbins BA; Spinosa JC; Leopard JD; Saven A; Piro LD
    Blood; 1994 Dec; 84(12):4310-5. PubMed ID: 7994047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
    Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
    Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
    Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
    Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine].
    Zák P; Chrobák L; Dĕdic K; Podzimek K
    Vnitr Lek; 2000 Oct; 46(10):697-703. PubMed ID: 11344629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine.
    Wheaton S; Tallman MS; Hakimian D; Peterson L
    Blood; 1996 Feb; 87(4):1556-60. PubMed ID: 8608247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia.
    Tallman MS; Hakimian D; Variakojis D; Koslow D; Sisney GA; Rademaker AW; Rose E; Kaul K
    Blood; 1992 Nov; 80(9):2203-9. PubMed ID: 1358262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
    Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V
    Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bone marrow changes in patients with hairy cell leukemia after 2-chlorodeoxyadenosine treatment].
    Urasiński I; Zdziarska B; Krygier-Stojałowska A
    Acta Haematol Pol; 1996; 27(1):49-55. PubMed ID: 8629443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
    Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
    Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey.
    Lauria F; Rondelli D; Zinzani PL; Bocchia M; Marotta G; Salvucci M; Raspadori D; Ventura MA; Birtolo S; Forconi F; Tura S
    Leukemia; 1997 May; 11(5):629-32. PubMed ID: 9180283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid massive splenic relapse of hairy cell leukemia (HCL) during bone marrow remission after 2-chlorodeoxyadenosine therapy: the spleen as a sanctuary site in HCL?
    Polliack A; Dann EJ
    Blood; 1994 Sep; 84(6):2057-8. PubMed ID: 8081009
    [No Abstract]   [Full Text] [Related]  

  • 15. New rearrangement pattern after treatment of hairy-cell leukemia with 2-chlorodeoxyadenosine.
    Schirmer M; Haun M; Grünewald K; Geisen F; Hilbe W; Thaler J; Konwalinka G
    Acta Haematol; 2000; 103(2):109-11. PubMed ID: 10838455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
    Rucińska M; Machaczka M; Załuska A; Skotnicki AB
    Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunohistochemical detection and quantification of minimal residual disease using DBA.44 antibodies in trephination biopsies of hairy cell leukemia].
    Dĕdic K; Zák P
    Cesk Patol; 2003 Oct; 39(4):175-7. PubMed ID: 14663929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission.
    Filleul B; Delannoy A; Ferrant A; Zenebergh A; Van Daele S; Bosly A; Doyen C; Mineur P; Glorieux P; Driesschaert P
    Leukemia; 1994 Jul; 8(7):1153-6. PubMed ID: 7913513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of patients with hairy cell leukemia (HCL) using a single cycle of 2-chloro-2'-deoxyadenosine (CdA).
    Jehn U; Gawaz M; Grunewald R; Hill W; Lorenz B; Stôtzer O
    Anticancer Res; 1993; 13(5C):1809-14. PubMed ID: 7903521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow and splenic histology in hairy cell leukaemia.
    Wotherspoon A; Attygalle A; Mendes LS
    Best Pract Res Clin Haematol; 2015 Dec; 28(4):200-7. PubMed ID: 26614898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.